Making precision cancer care a future reality requires novel approachesto finding treatment targets in cancers. Single-gene assays currently performed in clinical research laboratories are inadequate in the face of the rapidly growing list of genetic mutations that are potentially actionable. This presentation will focus on our experience in designing and running custom Ion AmpliSeq cancer gene panels on the Ion PGM System, an approach we are using to increase the understanding of genetic mutations in advanced cancers. Consideration will be given to detecting mutations of various types, as well as alterations in gene copy number. Critical pre-analytic factors and the integration of other technologies that define clinically significant targets
for future treatment will also be discussed.